NCT02201914 - Clomiphene Citrate Plus Gonadotropins and GnRH Antagonist Versus Flexible GnRH Antagonist Protocol Versus Microdose GnRH Agonist Protocol in Poor Responders Undergoing IVF | Biotech Hunter

Enrollment

250

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

October 31, 2014

Study Completion Date

November 30, 2014

Conditions

Poor RespondersIVFClomiphene CitrateGnRH AgonistGnRH Antagonist

Interventions

DRUG

Clomiphene citrate

patients receive clomiphene citrate 100 mg daily starting on day 2 for 5 days and 450 IU recombinant FSH and 225 IU recombinant LH daily starting on day 5; Cetrorelix 0,25 mg was administered daily when one or more follicle reached 13-14 mm in diameter until the hCG injection

DRUG

Daily FSH and LH plus Cetrorelix

Women receive an initial daily dose of 450 IU recombinant FSH and 225 IU recombinant LH starting on day 3; Cetrorelix 0,25 mg was administered daily when one or more follicle reached 13-14 mm in diameter until the hCG injection.

DRUG

Triptorelin plus daily FSH anh LH

women receive short-acting Triptorelin 0,05 mg daily starting on day 1 until the hCG injection and 450 IU recombinant FSH and 225 IU recombinant LH daily starting on day 2.

Trial Locations (1)

00197

RECRUITING

Bioroma, Rome